The Price of Global Health: Drug online Pricing Strategies to lowest Balance Patient Access and the Funding of Innovation online

The Price of Global Health: Drug online Pricing Strategies to lowest Balance Patient Access and the Funding of Innovation online

The Price of Global Health: Drug online Pricing Strategies to lowest Balance Patient Access and the Funding of Innovation online
The Price of Global Health: Drug online Pricing Strategies to lowest Balance Patient Access and the Funding of Innovation online_top

There is no writing/highlighting noted. Pages are smooth and clear, with no folds or creases. Minor wear to cover, everything is crisp and looks great. Fast Amazon shipping, delivery tracking number, no hassle return policy - your satisfaction is guaranteed!
See more
Sold by 4U Books and More and fulfilled by Amazon.
Access codes and supplements are not guaranteed with used items.
[{"displayPrice":"$108.14","priceAmount":108.14,"currencySymbol":"$","integerValue":"108","decimalSeparator":".","fractionalValue":"14","symbolPosition":"left","hasSpace":false,"showFractionalPartIfEmpty":true,"offerListingId":"j6n4u6mmP10RzuXr%2BjYc7g6Nn9E5zG2K68Xvkzt4oU0EGb07Nn2KtziJsOcJvzG4zY5nU0PvGv3TCJ1bOjU4tV0gWWlhRXGbjMseIqId%2Ba6eACA05oPkrUTZhEOtL1h7cOESgryfiK3afg6NNkwmOmc7EDagBITvlb6QzUGLuscEh0TjUUNmDdV0MfTipD46","locale":"en-US","buyingOptionType":"NEW"},{"displayPrice":"$51.02","priceAmount":51.02,"currencySymbol":"$","integerValue":"51","decimalSeparator":".","fractionalValue":"02","symbolPosition":"left","hasSpace":false,"showFractionalPartIfEmpty":true,"offerListingId":"lMwO28TIsBshQDIkDHIdzWD1YYKxeWdsEJy1jlKY5Fpue9NPS%2FSrWG5lbrnYX0IDHGky7IgyrcadQ%2F4AMdQVafM1EfIOsTpRTbwqXS6%2Fd%2F60kEBAly0HwLzVgzv0SGIzZD7JJf3o%2FWsOLKpBEqZ9ckvRZhWjDzBXuyxurpkSUk0AUWlxiEGr6jlmCt77%2BhiM","locale":"en-US","buyingOptionType":"USED"},{"displayPrice":"$38.27","priceAmount":38.27,"currencySymbol":"$","integerValue":"38","decimalSeparator":".","fractionalValue":"27","symbolPosition":"left","hasSpace":false,"showFractionalPartIfEmpty":true,"offerListingId":null,"locale":"en-US","buyingOptionType":"RENTAL"}]
$$108.14 () Includes selected options. Includes initial monthly payment and selected options. Details
Price
Subtotal
$$108.14
Subtotal
Initial payment breakdown
Shipping cost, delivery date, and order total (including tax) shown at checkout.
ADD TO LIST
Available at a lower price from other sellers that may not offer free Prime shipping.
SELL ON AMAZON
Share this product with friends
Text Message
WhatsApp
Copy
press and hold to copy
Email
Facebook
Twitter
Pinterest
Loading your book clubs
There was a problem loading your book clubs. Please try again.
Not in a club? Learn more
Join or create book clubs
Choose books together
Track your books
Bring your club to Amazon Book Clubs, start a new book club and invite your friends to join, or find a club that’s right for you for free. Explore Amazon Book Clubs
Brief content visible, double tap to read full content.
Full content visible, double tap to read brief content.

Book details

Brief content visible, double tap to read full content.
Full content visible, double tap to read brief content.

Description

Product Description

Public debate on the rising cost of new biotechnology drug treatments has intensified over the last few years as healthcare budget pressures have mounted under a strained economy. Meanwhile, the demand for new, effective medical and drug treatments continues to rise as unhealthy lifestyles cause further increases in diabetes and cardiovascular disease. Global drug pricing is one of the most hotly debated yet least understood aspects of the pharmaceutical industry. How should drug prices be set and what does it mean for patients? Why do governments increasingly get involved, and what is its impact on the global competitive environment? How can a life-saving industry have a poorer image than gun and tobacco industries, whose products are associated with death? Ed Schoonveld explains how pharmaceutical prices are determined in a complex global payer environment and what factors influence the process. His insights will help a wide range of audiences, from healthcare industry professionals to policy makers and the broader public, to gain a better understanding of this highly complex and emotionally charged field. The Price of Global Health is recognized as a valued and unique reference book that covers a complete array of topics related to global pharmaceutical pricing. It contains an in-depth but straightforward exploration of the pharmaceutical pricing strategy process, its underlying market access, general business and ethical considerations, and its implications for payers, physicians and patients. It is a much-needed and invaluable resource for anybody interested or involved in, or affected by, the development, funding and use of prescription drugs. In particular, it is of critical importance to pharmaceutical company executives and other leaders and professionals in commercialization and drug development, including marketing, business development, market access and pricing, clinical development, drug discovery, regulatory affairs, health outcomes, market research and public affairs. The second edition includes new chapters on payer value story development, oncology, orphan drugs and payer negotiations. Furthermore, many country chapters have been substantially updated to reflect changes in the healthcare systems, including the Affordable Care Act in the US, AMNOG in Germany, medico-economic requirements in France and many other country-specific changes. Lastly, almost every chapter has been updated with new examples and illustrations.

Review

Ed Schoonveld does an extraordinary job of making one of the most complex and vital topics in the industry intelligible to both new and experienced audiences. Best of all, he leverages case studies and straightforward frameworks to provide a pragmatic approach for mastering the theory of global pricing and access. I keep his book in easy reach for my own reference or to share with others. --Susanne Laningham, Executive Director Global Value Access & Policy, Amgen Inc.

This book gives a great overview and offers several perspectives on drug pricing issues. It provides comprehensive new insights such as the need to take benefits assessments of pharmaceuticals into consideration during all steps of drug development and market access. The mix of theory, in the form of underlying arguments and analytical frameworks, along with practical and up-to-date real-world solutions, makes this book an outstanding reference. --Thomas Mueller, Head of Pharmaceutical Department Gemeinsamer Bundesausschuss (Federal Joint Committee), Germany

The Price of Global Health is the most informative and comprehensive book I have read on the topic of global pharmaceutical pricing and market access. Ed is able to distill complex topics into simplified and pragmatic frameworks, including insightful perspectives on market segmentation, communicating value, and pricing. The final section provides a useful reference, describing how key global healthcare systems are structured and their approach for assessing value. I have recommended this book for members of my team as part of their initial training. --David Kaplan, Senior Advisor, Global Payer Market Research, Eli Lilly

About the Author

Ed Schoonveld is one of the leading experts in Global Pharmaceutical Pricing and Market Access. He has unparalleled experience as head of Global Market Access and Pricing functions in Wyeth, Lilly and BMS, and as a consulting leader in Cambridge/IMS and a number of other organizations. Ed is providing strategic consulting and research solutions to healthcare industry clients as Managing Principal and Practice Leader for the Market Access and Pricing practice at ZS Associates.

Product information

Brief content visible, double tap to read full content.
Full content visible, double tap to read brief content.

Videos

Help others learn more about this product by uploading a video!
Upload video
Brief content visible, double tap to read full content.
Full content visible, double tap to read brief content.

Customers who viewed this item also viewed

Customer reviews

4.3 out of 54.3 out of 5
3 global ratings

Top review from the United States

Valeria Suppini
5.0 out of 5 starsVerified Purchase
Five Stars
Reviewed in the United States on July 17, 2018
Amazing book for anybody starting out on market access and pricing!
Helpful
Report

Top reviews from other countries

Cassis
3.0 out of 5 starsVerified Purchase
Useful reference, but we still need the book on pricing and market access
Reviewed in the United Kingdom on October 10, 2015
This book tries to cover many key issues; one needs to be alert that the book is for market access/pricing people working in the pharmaceutical industry. Payers might like to read it as it will help explain the advice their suppliers are being given. The book''s subtitle is...See more
This book tries to cover many key issues; one needs to be alert that the book is for market access/pricing people working in the pharmaceutical industry. Payers might like to read it as it will help explain the advice their suppliers are being given. The book''s subtitle is a misnomer as the book does not connect drug pricing strategies to patient access and funding of innovation. The book is about how to get the best price in a drug market, which is quite a different thing. The book is weakened by models that are too US oriented, with the consequence that many central aspects of pricing logic that are driving reform are inadequately addressed. Much is missing or glossed over. HTA treatment is inadequate given the importance of quantitative and structured evidence requirements. There is no discussion of behavioural economics and structured decision-making within payer/seller encounters or within structured decision making by regulatory authorities. I couldn''t find tendering, indeed, procurement isn''t even in the index. Evidence generation is presented as a tactic to secure better pricing, rather than something science-based companies should be doing properly from the get-go. Including the van Westendorp approach on price estimation is amusing given it assumes that value and price can be determined in this way. The chapter on Managed Entry is dated. The inclusion of thumbnails sketches of a number of healthcare systems is not really useful as this information is widely available and in forms that are more amenable to analytical and pricing use in such areas as reference pricing, tendering practices, managed entry practices, etc. People in this business should already know this anyway. It would have been better to have organised the country content into the archetypes the author favours, and included in the main part of the book (I''m not trying to rewrite the book, just suggest this section is almost immediately dated and takes up 100 or so pages of an already expensive book.) For a book of this scale, a surprisingly small bibliography. It may be that pharmacos have no idea what they should charge for a medicine and can only use prices that a market will bear, but we can only hope this isn''t the case. However, as this review is being written, we are learning of dramatic drug price increases in the US. We do need new thinking on pricing, and I would have hoped this book could have taken us in this direction, but it doesn''t. So, market access and pricing people will continue to misunderstand payers and the evolving pharmaceutical market.
3 people found this helpful
Report
See all reviews
Brief content visible, double tap to read full content.
Full content visible, double tap to read brief content.

Pages with related products.

  • social selling
  • ethics of marketing

The Price of Global Health: Drug online Pricing Strategies to lowest Balance Patient Access and the Funding of Innovation online

The Price of Global Health: Drug online Pricing Strategies to lowest Balance Patient Access and the Funding of Innovation online

The Price of Global Health: Drug online Pricing Strategies to lowest Balance Patient Access and the Funding of Innovation online

The Price of Global Health: Drug online Pricing Strategies to lowest Balance Patient Access and the Funding of Innovation online

The Price of Global Health: Drug online Pricing Strategies to lowest Balance Patient Access and the Funding of Innovation online

The Price of Global Health: Drug online Pricing Strategies to lowest Balance Patient Access and the Funding of Innovation online

The Price of Global Health: Drug online Pricing Strategies to lowest Balance Patient Access and the Funding of Innovation online

The Price of Global Health: Drug online Pricing Strategies to lowest Balance Patient Access and the Funding of Innovation online

The Price of Global Health: Drug online Pricing Strategies to lowest Balance Patient Access and the Funding of Innovation online

The Price of Global Health: Drug online Pricing Strategies to lowest Balance Patient Access and the Funding of Innovation online

The Price of Global Health: Drug online Pricing Strategies to lowest Balance Patient Access and the Funding of Innovation online

The Price of Global Health: Drug online Pricing Strategies to lowest Balance Patient Access and the Funding of Innovation online

The Price of Global Health: Drug online Pricing Strategies to lowest Balance Patient Access and the Funding of Innovation online

The Price of Global Health: Drug online Pricing Strategies to lowest Balance Patient Access and the Funding of Innovation online

The Price of Global Health: Drug online Pricing Strategies to lowest Balance Patient Access and the Funding of Innovation online

The Price of Global Health: Drug online Pricing Strategies to lowest Balance Patient Access and the Funding of Innovation online